Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages

International Journal of Cancer

Volumn 71, Issue 3, 1997, Pages 451-455

  Landström, Maréne ^a,b,c   Funa, Keiko ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; TACROLIMUS;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CASTRATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSIS; ESTROGEN THERAPY; GROWTH INHIBITION; IMMUNOCOMPETENT CELL; MACROPHAGE ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL DIVISION; ESTRADIOL; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATS; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TUMOR CELLS, CULTURED;

EID: 0030996038     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970502)71:3<451::AID-IJC24>3.0.CO;2-H     Document Type: Article

References (22)

1. ADAMS, D.O. and NATHAN, C.F., Molecular mechanisms in tumor-cell killing by activated macrophages. Immunol. Today, 4, 166-170 (1983).
2. BLANKENSTEIN, T., QIN, Z., ÜBERLA, K., MÜLLER, W., ROSEN, H., VOLK, H.D. and DIAMANTSTEIN, T.J., DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cells, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant. J. exp. Med., 173, 1047-1052 (1991).
3. FEALY, M.J., MOST, D., HUIE, P., WOLF, M., SIBLEY, R.K., MORRIS, R.E. and PRESS, B.H.J., Association of down-regulation of cytokine activity with rat hind limb allograft survival. Transplantation. 59, 1475-1480 (1995).
4. FERGUSSON, J.D. and FRANKS, L.M., The response of prostatic carcinoma to oestrogen treatment. Brit. J. Surg., 40, 422-428 (1953).
5. FERRO, M.A., Use of intravenous stilbestrol diphosphate in patients refractory to conventional hormonal manipulation. Urol. Clin. North Amer., 18, 139-143 (1991).
6. FRUMAN, D.A., KLEE, C.B., BIERBER, B.E. and BURAKOFF, S., Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. nat. Acad. Sci. (Wash.), 89, 3686-3690 (1992).
7. HIBBS, J.B. JR., VAVRIN, Z. and TAINTOR, R.R., L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol., 138, 550-565 (1987).
8. HOCK, M., DORSCH, M., KUNZENDORF, U., QIUN, Z., DIAMANTEIN STEIN, T. and BLANKENSTEIN, T., Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor or interferon-γ. Proc. nat. Acad. Sci. (Wash.), 90, 2774-2778 (1993).
9. HUGGINS, C. and HODGES, C.V., Studies of prostatic cancer. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1, 293-297 (1941).
10. INAMURA, N., NAKAHARA, K., KINO, T., GOTO, T., AOKI, H., YAMAGUCHI, I., KOHSAKA, M. and OCHIAI, T., Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK 506. Transplantation, 45, 206-209 (1988).
11. ISAACS, J.T., Development and characterizations of the available model systems for the study of the prostatic cancer. In: D.S. Coffey, N.
12. Bruchovsky, W.H. Gardner, M.J. Resnik and J.P. Kerr (eds.), Current concepts and approaches to the study of prostate cancer, pp. 513-576, A.R. Liss, New York (1987).
13. KYPRIANOU, N., ENGLISH, H.F. and ISAACS, J.T., Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 90, 3748-3753 (1990).
14. LANDSTRÖM, M., BERGH, A., TOMIC, R. and DAMBER, J.-E., Estrogen treatment combined with castration alone inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma. Prostate, 17, 57-68 (1990).
15. LANDSTRÖM, M., DAMBER, J.E. and BERGH, A., Prostatic tumour regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res., 54, 4281-1284 (1994).
16. LANDSTRöM, M., EKLÖV. S., COLOSETTI, P., NILSSON, S., DAMBER, J.-E., BERGH, A. and FUNA, K., Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-β1 and its type I and type II receptors. Int. J. Cancer, 67, 573-579 (1996).
17. LEPOR, H., Ross, A. and WALSH, P.C., The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol. 128, 335-340 (1982).
18. NATHAN, C.F., BRUKNER, L.H., SILVERSTEIN, S.C. and COHN, Z.A., Extracellular cytolysis of activated macrophages and granulocytes: I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J. exp. Med., 149, 84-99 (1979).
19. SCHMID, D.S., TITE, J.P. and RUDDLE, N.H., DNA fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cells, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant. Proc. nat. Acad. Sci. (Wash.), 83, 1881-1885 (1986).
20. SZENDE, B., ROMICS, I. and VASS, L., Apoptosis in prostate cancer after hormonal treatment. Lancet, 342, 1422 (1993).
21. VAUX, D.L., Toward an understanding of the molecular mechanisms of physiological cell death. Proc. nat. Acad. Sci. (Wash.), 90, 786-789 (1993).
22. WAHL, S.M., HUNT, D.A., WAKEFIELD, L.M., MCCARTHY-FRANCIS, N., WAHL, M.M., ROBERTS, A.B. and SPORN, M.B., Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc. nor. Acad. Sci. (Wash.), 84, 5788-5792 (1987).